[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscle-weakness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscle-weakness":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,45,74,101,133,158,188,217,262,287,318,345,374,409,437,466,500,529,550,580,606,636,658,684,707],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100592799","toward-ubiquitous-lower-limb-exoskeleton-use-in-children-and-young-adults-100592799",false,"NCT06998134","Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults","Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults: Exploratory Observational Analysis of Novel Robotic Control Strategies","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Provision of signed and dated separate informed consent and assent forms for screening purposes. Upon inclusion in the protocol, provision of signed and dated informed consent and assent forms to begin participation in the study will be necessary.\n* Stated willingness to comply with all study procedures and availability for the duration of the study, or alternatively, ability to do so based on parent report and physician observation during history and physical examination.\n* Age 5 to 25 years old. Importantly, we included young adults (18-25 years old) because longterm outcomes for adults with cerebral palsy include loss of ambulatory ability. While studies of conventional gait training in this population have been conducted, use of exoskeletons in this population is very limited. Given the potential benefit of exoskeletons to reduce knee extension deficiency, it is important to determine whether novel controllers we develop are also tolerated and effective in this age group.\n* Either has a gait pathology arising from a diagnosis of CP, MD, SB, or iSCI or has no gait pathology.\n* Knee joint range of motion of at least 25 degrees in the sagittal plane (knee extension\u002Fflexion) assessed with the hip extended in a supine position. Hamstring contracture as assessed by the straight leg raising test does not limit ability to participate in the study.\n* Ankle joint range of motion of at least 15 degrees in the sagittal plane (dorsi-plantarflexion) with the foot in neutral alignment.\n* Able to walk at least 10 feet without stopping with or without a walking aid.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Any neurological, musculoskeletal, or cardiorespiratory injury, health condition, or diagnosis other than CP, MD, SB, or iSCI that would affect the ability to walk as directed with the robotic exoskeleton.\n* A history of uncontrolled seizures in the past year.\n* Pregnancy based on self-reporting. We excluded pregnancy due to confounding factors of pregnancy on gait.\n* Adult unable to consent for themselves at screening visit.","ALL","5 Years","25 Years",{"count":20,"type":21},23,"ESTIMATED","OBSERVATIONAL","People with cerebral palsy (CP), muscular dystrophy (MD), spina bifida, or spinal cord injury often have muscle weakness, and problems moving their arms and legs. The NIH designed a new brace device, called an exoskeleton, that is worn on the legs and helps people walk. This study is investigating new ways the exoskeleton can be used in multiple settings while performing different walking or movement tasks, which we call ubiquitous use. For example, we will ask you to walk on a treadmill at different speeds, walk up and down a ramp, or walk through an obstacle course. Optionally, the exoskeletons may also use functional electrical stimulation (FES), a system that sends electrical pulses to the muscle to help it move the limb.",[25,26],"Muscle Weakness","Problems Moving Their Arms and Legs",[28,29,30,31],"Cerebral Palsy (CP)","muscular dystrophy (MD)","Spina Bifida","incomplete spinal cord injury","RECRUITING","2026-06-26",{"date":35,"type":36},"2026-06-29","ACTUAL",{"date":38,"type":36},"2026-06-23",{"date":40,"type":21},"2028-08-18",{"name":42,"class":43},"National Institutes of Health Clinical Center (CC)","NIH",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100480539","muscle-recovery-after-critical-illness-100480539","NCT05537298","Muscle Recovery After Critical Illness","Cellular and Physical Function Outcomes Leading to Failed Muscle Recovery After Critical Illness\u002FMuscle and Physical Functional Recovery After Acute Critical Illness","TRACER","Inclusion Criteria:\n\n* adult (\\>18 y\u002Fo)\n* admission for sepsis or acute respiratory failure with at least 72 hour stay in ICU\n\nExclusion Criteria:\n\n* patients who were not ambulatory prior to ICU admission\n* experienced \\>2 ICU admissions in the past year (chronic or recurrent critical illness due to the same or different reason\n* patients not expected to survive \\~6months after admission\n* acute or chronic neurologic condition\n* acute or chronic orthopedic condition preventing strength\u002Ffunctional testing\n* morbid obesity \\>50 kg\u002Fm2 due to distortion of muscle ultrasonography","MALE","18 Years",{"count":56,"type":21},209,"The overarching goal of the proposed study is to determine the trajectories of physical recovery and cellular markers involved with the underlying failure to recover muscle after critical illness, while exploring which characteristics are associated with sustained physical disability. This proposal will examine muscle pathophysiology carefully aligned with physical function outcomes in order to longitudinally assess the recovery, or failed recovery, of muscle function in participants after critical illness:\n\n1. to examine the recovery of muscle and physical function in ICU survivors through longitudinal assessments\n2. to investigate the underlying cellular markers and mechanisms of muscle recovery in ICU survivors\n3. to determine which cellular markers contribute to physical disability in ICU survivors up to 1 year after hospital admission",[59,60,25,61],"ICU Acquired Weakness","Post Intensive Care Unit Syndrome","Critical Illness",[63,64],"skeletal muscle","physical function",{"date":33,"type":36},{"date":67,"type":36},"2022-10-18",{"date":69,"type":21},"2027-08-01",{"name":71,"class":72},"Esther Dupont-Versteegden","OTHER",3,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":44},"100633808","muscle-aging-phenotypes-in-childhood-cancer-survivors-100633808","NCT07531498","Muscle Aging Phenotypes in Childhood Cancer Survivors","Inclusion Criteria:\n\n* Age 18 years old or older at time of consent and enrolled in SJLIFE.\n* Participant (100 per group for a total of 400) is\u002Fhas:\n* Group 1: No cancer history\n* Group 2: Age and sex specific relative lean mass z-score of less than -0.5 OR age and sex specific hand grip or isokinetic (60 degrees\u002Fsec) quadriceps strength z-score of \\\u003C-0.5 AND exposure to a peripheral neurotoxin.\n* Group 3: Age and sex specific relative lean mass z-score of less than -0.5 OR age and sex specific hand grip or isokinetic (60 degrees\u002Fsec) quadriceps strength z-score of \\\u003C-0.5 AND NOT exposed to a peripheral neurotoxin.\n* Group 4: Age and sex specific relative lean mass z-score of less than -0.5 AND age and sex specific hand grip strength or isokinetic (60 degrees\u002Fsec) quadriceps strength z-score of \\\u003C-0.5 REGARDLESS of exposure status.\n* Participant or legal guardian is able and willing to give informed consent.\n\nExclusion Criteria:\n\n* Presence of implanted medical devices or metal that would interfere with MRI or MRS.\n* Female Participant is pregnant.\n* Body weight exceeding 300 pounds, due to MRI restrictions.\n* Inability to lie flat on his\u002Fher back for 90 minutes or longer for MRI.\n* Inability or unwillingness of research participant or legal guardian\u002Frepresentative to give written informed consent.",true,{"count":82,"type":21},533,"Childhood cancer survivors experience premature declines in muscle mass, strength, and physical function that contribute to morbidity and early mortality. The biological mechanisms driving these impairments are heterogeneous and poorly understood. This observational study aims to characterize distinct muscle health endotypes in adult survivors of childhood cancer using advanced imaging, neuromuscular testing, and functional assessment. Survivors with reduced muscle health and community controls will undergo multimodal magnetic resonance imaging and spectroscopy, nerve conduction studies, surface electromyography, body composition assessment, and physical performance testing during a single study visit integrated into an ongoing cohort evaluation. Identifying mechanistic endotypes of impaired muscle health will support development of targeted interventions to preserve function and improve long-term outcomes in childhood cancer survivors.\n\nPrimary Objective:\n\n\\- Characterize reduced muscle health endotypes in childhood cancer survivors.\n\nSecondary Objective:\n\n\\- Identify specific treatment and lifestyle related risk factors for each reduced muscle health endotype.\n\nExploratory Objective:\n\n\\- Host germline genetics will be associated with specific muscle endotypes.",[25,85,86],"Low Muscle Mass","Sarcopenia",[88,89,90,91],"Childhood Cancer Survivors","Adult Survivors of Childhood Cancer","Neuromuscular Function","Muscle Health","NOT_YET_RECRUITING","2026-06-22",{"date":38,"type":36},{"date":96,"type":21},"2026-10-01",{"date":98,"type":21},"2031-05",{"name":100,"class":72},"St. Jude Children's Research Hospital",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":80,"sex":108,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":44},"100605721","mitigating-neural-hypoexcitability-and-weakness-during-disuse-in-women-100605721","NCT07166198","Mitigating Neural Hypoexcitability and Weakness During Disuse in Women","MiND","Inclusion Criteria:\n\n* Women between 40-65 years of age\n* Baseline handgrip strength \\>16Kg\n\nExclusion Criteria:\n\n* Personal or family history of blood clots\n* Current use of anticoagulant medications\n* Neuromuscular or metabolic diseases (e.g., multiple sclerosis, diabetes)\n* Arthritis\n* Osteoporosis or osteopenia\n* History of myocardial infarction within the past year\n* Chronic pain ≥3\u002F10 for ≥3 months\n* Uncontrolled hypertension (≥140\u002F90 mmHg)\n* Upper extremity surgery within the past year\n* Use of assistive hand or arm device within the past year\n* Fall involving the upper extremities within the past year\n* Upper extremity injuries preventing safe participation\n* Current use of muscle relaxants, benzodiazepines, or similar drugs\n* Smoking within the past 6 months\n* History of drug or alcohol abuse within the past year\n* Severe anxiety or claustrophobia\n* Pregnancy (current or planned)\n* Allergies to medical adhesives\n* High risk of sarcopenia (per SARC-F)\n* Contraindications to TMS or MRI\n* Upper-body resistance training within the past 6 months\n* Inability\u002Funwillingness to refrain from resistance training during study","FEMALE","40 Years","65 Years",{"count":112,"type":21},20,"INTERVENTIONAL",[115],"NA","Clinical trial The goal of this clinical trial is to learn how muscle weakness and atrophy develop during short periods of arm immobilization and whether a type of exercise called cross-education can help reduce these effects in women at midlife.\n\nThe main questions it aims to answer are:\n\nWhat changes happen in the nervous system that lead to weakness when a wrist is immobilized?\n\nCan training the opposite arm help maintain muscle strength, muscle size, and nervous system function in the immobilized arm?\n\nResearchers will compare women who have their wrist immobilized with or without opposite-arm resistance training.\n\nParticipants will:\n\nWear a wrist cast on one arm for 7 days\n\nComplete strength training with the opposite arm or no training, depending on their group\n\nAttend study visits for strength and nervous system testing\n\nHave non-invasive tests (like magnetic brain stimulation, muscle recordings, and muscle imaging) to measure how the nervous system and muscle responds",[25],[119,120,121,122,123],"Resistance Training","Neuroplasticity","Muscle Disuse","Wrist immobilization","Women's Health","2026-06-09",{"date":126,"type":36},"2026-06-10",{"date":128,"type":36},"2026-05-01",{"date":130,"type":21},"2027-01-31",{"name":132,"class":72},"Kansas State University",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":80,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":113,"phases":141,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":44},"100579067","imaging-skeletal-muscle-mitochondrial-oxphos-activity-in-acute-lymphoblastic-leukemia-survivors-100579067","NCT06819475","Imaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors","Inclusion Criteria:\n\n* Survivor- or Control-Participant is age 18 years old or older at time of consent and enrolled in SJLIFE.\n* Survivor- Participant is childhood ALL survivor\n* Survivor- or Control Participant has low muscle mass as defined by relative lean mass z-score of less than or equal to -0.5 SD (lean mass divided by height in meters squared).\n* Survivor - Participant is able and willing to give informed consent\n\nExclusion Criteria:\n\n* Survivor-Participant has history of cranial radiation.\n* Survivor- or Control-Participant has implanted medical devices or metal that would interfere with MRI or MRS\n* Female Survivor- or Control-Participant is pregnant.\n* Survivor- or Control-Participant is taking anticoagulants (e.g. aspirin, apixaban, coumadin, edoxaban, rivaroxaban)\n* Survivor- or Control-Participant weighs more than 300 pounds.\n* Survivor- or Control-Participant is allergic to local anesthetic (i.e., lidocaine, bupivacaine).\n* Survivor- or Control-Participant cannot lie flat on his\u002Fher back for 90 minutes or longer\n* Survivor- or Control-Participant has a current history of peripheral motor neuropathy.",{"count":140,"type":21},60,[115],"The participants are being asked to take part in this trial, because the participant is a survivor of childhood cancer or agreed to be part of a volunteer group to understand the relation between cancer and cancer treatment and muscle weakness in survivors of Acute Lymphoblastic Leukemia (ALL). ALL is cancer of the blood and bone marrow.\n\nPrimary Objective\n\n• To compare muscle mtOXPHOS activity and satellite cell content among ALL survivors and controls.\n\nSecondary Objective\n\n* To evaluate the association between muscle mtOXPHOS, muscle satellite cell content and physical performance in ALL survivors.\n* To evaluate the association of muscle morphology and epigenetics with muscle mtOXPHOS in ALL survivors.",[144,25],"Childhood Cancer",[146,147,148,16,149],"Survivor","Acute Lymphoblastic Leukemia","Adult","Healthy Volunteer","2026-05-14",{"date":152,"type":36},"2026-05-18",{"date":154,"type":36},"2025-06-02",{"date":156,"type":21},"2028-01",{"name":100,"class":72},{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":80,"sex":16,"minAge":54,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":113,"phases":167,"briefSummary":168,"conditions":169,"keywords":174,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":44},"100526005","effect-of-weight-loss-on-intermuscular-adipose-tissue-imat-signaling-100526005","NCT06129110","Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling","Inclusion Criteria:\n\n* Generally healthy men and women aged 18-70\n* BMI between 30-40\n* Less than 1 hour of exercise per week\n* Women:\n\n  1. may be pre or post menopausal\n\nExclusion Criteria:\n\n* Type 1 or Type 2 diabetes\n* Thyroid disease\n* History of lung disease\n* Active use of nicotine\n* Severe plasma lipid disorders\n* Taking hormone replacement drugs, blood thinners, or thiazoladinediones\n* Women:\n\n  1. Currently going through menopause or peri-menopause\n  2. Pregnant or breastfeeding\n  3. History of Polycystic Ovary Syndrome","70 Years",{"count":166,"type":21},70,[115],"The goal of this intervention study is to learn about how weight loss impacts molecular signaling of intermuscular adipose tissue (IMAT) in individuals with obesity. The main question it aims to answer is how inflammatory molecules secreted by IMAT promote muscle insulin resistance and inflammation, and how these same molecules are diminished after weight loss. Following screening visits involving body composition measures, blood testing, strength testing, and a thigh muscle biopsy, participants will go through a 12-week dietary intervention for weight loss. After 12 weeks, this will be followed by the same testing and biopsies that were completed before the intervention. Researchers will then compare outcomes of individuals who lost weight to individuals who did not lose weight.",[170,171,25,172,173],"Obesity","Insulin Sensitivity","Adiposity","Insulin Resistance",[175,176,177,178],"IMAT","Intermuscular Adipose Tissue","Weight Loss","Diet","2026-05-13",{"date":181,"type":36},"2026-05-15",{"date":183,"type":36},"2024-01-31",{"date":185,"type":21},"2028-09-01",{"name":187,"class":72},"University of Colorado, Denver",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":197,"conditions":198,"keywords":204,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":73},"100347976","metabolomics-study-on-postoperative-intensive-care-acquired-muscle-weakness-100347976","NCT03810768","Metabolomics Study on Postoperative Intensive Care Acquired Muscle Weakness","Metabolomics Pilot Study on Postoperative Intensive Care Acquired Muscle Weakness (MIRACLE-I Study)","MIRACLE I","Inclusion Criteria:\n\n* invasive mechanically ventilated critically ill patient with expected intensive care unit stay \\> 3 days\n* postoperative patient\n* ≥ 18 years old\n* American Society of Anesthesiology (ASA) classification ≥ III\n\nExclusion Criteria:\n\n* moribund patient\n* non-curative care (comfort care)",{"count":112,"type":21},"In this mono-center pilot trial, surgical patients who are at high risk to be admitted to intensive care will be screened and asked for participation. We are going to take blood and muscle samples at respecified time points to do metabolic, histological and molecular testing.\n\nAim of the study is to investigate (1) changes of the blood metabolome in patients with ICUAW (intensive care unit acquired weakness) and (2) identify metabolic components who are responsible for ICUAW or can be used as marker for ICUAW.",[199,200,61,201,202,203,25],"Metabolomics","Critical Care","Critical Illness Myopathy","Critical Illness Polyneuropathy","Intensive Care (ICU) Myopathy",[205,206,207],"pilot trial","muscle biopsy","blood metabolome","2026-02-28",{"date":210,"type":36},"2026-03-03",{"date":212,"type":36},"2022-09-02",{"date":214,"type":21},"2026-12-31",{"name":216,"class":72},"Technical University of Munich",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":113,"phases":225,"briefSummary":227,"conditions":228,"keywords":235,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":261},"100564264","phase-1-a-phase-1-study-of-anitocabtagene-autoleucel-for-the-treatment-of-subjects-with-non-oncology-plasma-cell-related-diseases-100564264","NCT06626919","A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases","Inclusion Criteria:\n\n* Subject must be 18 years of age or older\n* Must have MGFA clinical classification Grades 2-4A at time of screening\n* Subject must have clinically active disease and requiring ongoing therapy for GMG\n* MG-ADL score 6 and QMG score \\>10 at screening\n* GMG specific autoantibodies must be above the reference laboratory ULN\n\nExclusion Criteria:\n\n* Subject is pregnant or breastfeeding\n* Treatment with Anti-CD20 agents, calcineurin inhibitors, FcRN inhibitors, azathioprine, mycophenolate mofetil, methotrexate, or cyclophosphamide within the specified time frame prior to leukapheresis or prior to anito-cel infusion\n* Previous treatment with any gene therapy, chimeric antigen receptor therapy or T cell engager\n* Previous thymectomy within 6 months of screening\n* Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator",{"count":224,"type":21},30,[226],"PHASE1","A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.",[229,230,231,232,233,234,25],"Muscular Diseases","Neuromuscular Manifestations","Autoimmune","Autoimmune Diseases","Autoimmune Diseases of the Nervous System","Myasthenia Gravis",[236,237,238,239,240,241,242,243,234,244,245,246,247,248,249,250],"ARC-311","CART","CAR-T","BCMA","Anito-cel","Generalized Myasthenia Gravis","gMG","MG","non-oncology plasma cell","autoimmune","auto-antibody","chimeric antigen receptor","D-Domain chimeric antigen receptor","B-cell maturation antigen (BCMA)","anitocabtagene autoleucel","2026-02-24",{"date":253,"type":36},"2026-02-25",{"date":255,"type":36},"2025-04-30",{"date":257,"type":21},"2028-04",{"name":259,"class":260},"Arcellx, Inc.","INDUSTRY",13,{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":113,"phases":271,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":283,"leadSponsor":285,"locationsCount":44},"100626420","reduction-of-muscle-catabolism-through-brain-activation-in-burn-patients-100626420","NCT07435402","Reduction of Muscle Catabolism Through Brain Activation in Burn Patients","Reduction of Muscle Catabolism Through Brain Activation in Burn Patients (REMBRANT)","REMBRANT","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Severe burn injury involving more than 30% of total body surface area (TBSA)\n* Admission to the intensive care unit\n* Expected need for invasive mechanical ventilation and continuous sedation for at least 7 days\n* Ability to obtain written informed consent from the patient or a legally authorized representative\n\nExclusion Criteria:\n\n* Pre-existing severe neuromuscular or neurodegenerative disease\n* Known contraindication to inhalational sedation with isoflurane\n* Pregnancy or breastfeeding\n* Participation in another interventional clinical trial that could interfere with the study outcomes\n* Any condition that, in the opinion of the investigator, would make participation in the study unsafe or interfere with protocol adherence",{"count":224,"type":21},[115],"Patients with extensive burn injuries frequently develop severe skeletal muscle wasting and weakness as part of critical illness-related myopathy and neuropathy. This condition delays ventilator weaning, prolongs intensive care unit (ICU) and hospital stay, and contributes to long-term functional impairment and reduced quality of life. In burn patients, muscle loss is particularly pronounced during the early post-injury phase and is associated with mitochondrial dysfunction and altered neuromuscular signaling.\n\nEffective strategies to prevent muscle catabolism in critically ill burn patients remain limited. Although early active rehabilitation is beneficial, many patients are unable to participate due to deep sedation, mechanical ventilation, or clinical instability. Therefore, innovative rehabilitation approaches applicable during the acute phase of critical illness are needed.\n\nThe REMBRANT (REduction of Muscle catabolism through BRAin activation in burn patieNTs) study is a single-center, randomized, controlled, open-label clinical trial evaluating whether a multimodal brain-activating rehabilitation strategy can attenuate skeletal muscle loss in adult patients with severe burns. Thirty patients with burns involving more than 30% of total body surface area who require invasive mechanical ventilation and prolonged sedation will be randomized in a 1:1 ratio to standard care or an intervention group.\n\nBoth groups will receive standardized burn treatment and conventional rehabilitation. The intervention group will additionally receive the Burn-Bundle Extended Rehabilitation Program, combining inhalational isoflurane sedation with functional proprioceptive stimulation, repetitive transcranial magnetic stimulation, and virtual reality-assisted rehabilitation when clinically feasible.\n\nThe primary outcome is change in skeletal muscle mass and strength. Secondary outcomes include ICU length of stay, ventilator-free days, mitochondrial function, and health-related quality of life.",[274,61,25],"Burns - Multiple",[276,277,278],"extensive burn injury","skeletal muscle wasting","brain activation","2026-02-21",{"date":281,"type":36},"2026-02-27",{"date":128,"type":21},{"date":284,"type":21},"2030-06-30",{"name":286,"class":72},"Charles University, Czech Republic",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":293,"targetDuration":295,"studyType":22,"phases":4,"briefSummary":296,"conditions":297,"keywords":302,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":73},"100624720","investigation-of-preoperative-factors-influencing-the-outcome-of-motor-deficits-in-patients-undergoing-lumbar-microdiskectomy-100624720","NCT07413302","Investigation of Preoperative Factors Influencing the Outcome of Motor Deficits in Patients Undergoing Lumbar Microdiskectomy","Inclusion Criteria:\n\n* Patients suffering from lower limb paresis (motor deficit) caused by lumbar disk herniation undergoing a single-level microdiskectomy\n* Age (years) \\> 17\n\nExclusion Criteria:\n\n* Age (years) \\\u003C 18\n* Medical history of lumbar spine surgery\n* Absence of limb paresis\n* Motor deficit caused by other than disk herniation aetiologies\n* Reoperation within 6 months after microdiskectomy\n* Microdiskectomy at more than one level\n* Cauda equina syndrome\n* Peripheral neuropathy",{"count":294,"type":21},40,"6 Months","Lumbar disc herniations may result in lower limb weakness. In such cases, there is a strong indication for surgical intervention through microdiscectomy. This clinical study aims to investigate preoperative factors that may influence the postoperative outcomes of patients undergoing this procedure.",[298,299,25,300,301],"Motor Deficits","Lumbar Discectomy","Paresis","Lumbar Disc Herniation",[303,304,305,306,307,308],"microdiscectomy","lumbar disc herniation","motor deficit","lower limb paresis","prognostic factors microdiscectomy","disc herniation outcome","2026-02-09",{"date":311,"type":36},"2026-02-17",{"date":313,"type":36},"2024-07-03",{"date":315,"type":21},"2026-12",{"name":317,"class":72},"Aristotle University Of Thessaloniki",{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":80,"sex":108,"minAge":54,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":113,"phases":328,"briefSummary":329,"conditions":330,"keywords":333,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":44},"100546482","thrive-well-cancer-fdtnexercisecreatine-supplementation-100546482","NCT06395506","THRIVE Well Cancer FDTN\u002FExercise_Creatine Supplementation","An Open-label Randomized Trial of Exercise ± Creatine Supplementation to Augment the Adaptations of Exercise Training in Cancer Survivors","THRIVE","Inclusion criteria (Breast Cancer Group)\n\n* Age 18-75 years of age\n* Diagnosis of breast cancer requiring chemotherapy\n* Recent (within 6 months) completion of chemotherapy\n* Willing to attend 3 virtual-based exercise sessions per week\n* Able to take oral medications\n* Participant is willing and able to provide consent to participating in the study\n* Serum creatinine ≤ 1.5 x ULN or Estimated glomerular filtration rate (eGFR) ≥30 mL\u002Fmin\u002F1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation.\n\nExclusion criteria (Breast Cancer Group)\n\n* Physical indications where performing exercise may be limited and\u002For contraindicated\n* Poorly controlled hypertension (blood pressure \\> 160\u002F95mmHg)\n* Current tobacco use (within 6 months)\n* Anabolic steroids use\n* Pitting edema greater than 2+\n* Currently undergoing chemotherapy treatment for cancer\n* History of moderate-severe heart disease (New York Heart Classification greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of stairs or less; abnormal breath sounds on auscultation)\n* Pregnant or plan to become pregnant during the study\n* Recent (within one month) or anticipated treatment with corticosteroids (except for short term use during the time of chemotherapy), or other appetite stimulants\n* Serum creatinine \\> 1.5 x ULN or Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation\n* Currently taking creatine supplements\n* Lack of availability to a smartphone and\u002For internet\n\nInclusion Criteria (Healthy Age-matched Control Group)\n\n* Age 18-75 years of age\n* Have never been diagnosed with cancer\n* Willing to provide consent to participate in this study\n\nExclusion Criteria (Healthy Age-matched Control Group)\n\n* Physical indications where performing exercise may be limited and\u002For contraindicated\n* Poorly controlled hypertension (blood pressure \\> 160\u002F95mmHg)\n* Current tobacco use (within 6 months)\n* Anabolic steroids use\n* Pitting edema greater than 2+\n* History of cancer diagnosis\n* History of moderate-severe heart disease (New York Heart Classification greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of stairs or less; abnormal breath sounds on auscultation)\n* Pregnant or currently taking prescribed medication to prepare for pregnancy (i.e.\n\nhormonal therapy for IVF)\n\n* Recent (within one month) treatment with corticosteroids\n* Recent (within one month) use of appetite stimulants or appetite suppressants\n* Serum creatinine \\> 1.5 x ULN or Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation\n* Diagnosed Bipolar Disorder or MDQ score indicative of bipolar disorder or Neurological disorders\n* Uncontrolled diabetes (A1c of 6.5% or higher)\n* Currently taking creatine supplements\n* Lack of availability to a smartphone and\u002For internet","75 Years",{"count":140,"type":21},[115],"The study's purpose is to evaluate whether creatine supplementation can help breast cancer survivors respond quicker to exercise by improving strength, endurance, and body composition. We are seeking to compare information collected from healthy woman of the same age who have never had breast cancer to those participants who have had breast cancer and undergone chemotherapy treatment.",[331,332,25],"Breast Cancer","Breast Cancer Female",[331,332,334,335],"Exercise","Creatine Supplement","2025-12-17",{"date":338,"type":36},"2025-12-24",{"date":340,"type":36},"2024-10-29",{"date":342,"type":21},"2028-05-31",{"name":344,"class":72},"The University of Texas Medical Branch, Galveston",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":80,"sex":16,"minAge":352,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":113,"phases":356,"briefSummary":357,"conditions":358,"keywords":360,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":44},"100564582","fit-exercise-in-30d-of-ulls-induced-muscle-disuse-100564582","NCT06631053","FIT Exercise in 30d of ULLS-induced Muscle Disuse","Use of Velocity Monitoring to Prescribe Appropriate Flywheel-based Inertial Training (FIT) Workloads for Exercise in Space Flight","Inclusion Criteria:\n\n* Regularly engaging in aerobic exercise (\\> 150min\u002Fwk) and resistance exercise (\\>1 time per week) for the past 12 months\n* Education greater than or equal to bachelor's degree (any field)\n\nExclusion Criteria:\n\n* Waist circumference \\\u003C 55cm or \\> 90cm (F) and \\\u003C 75cm or \\> 100cm (M)\n* Body mass index \\\u003C 18.5 or \\> 29.9\n* Shoe size \\\u003C 25 or \\>29cm.\n* Not regularly engaging in exercise for previous 12 months\n* Tobacco use within previous 6 months\n* Blood clotting disorder\n* Heart arrhythmia\n* Implanted device which could negatively be affected by electrical impulse or strong magnetic field such as pacemaker, internal defibrillator, or cochlear implant\n* Diagnosed cardiovascular, pulmonary, renal, or metabolic disease\n* Pregnancy (within previous 6 months)\n* Oral contraceptive use (within previous three months)\n* High resting blood pressure (\\>140 systolic and\u002For \\> 90 diastolic)\n* Currently or previously undergone gender-affirming therapy (hormone therapy or sexual reassignment surgery)\n* Low back or leg injury in previous 6 months\n* Currently taking medication to assist with sleep\n* Muscle, bone, or joint injury that limits physical activity within previous 6 months\n* Neurological disorder which affects balance (such as multiple sclerosis or Parkinson's disease)","35 Years","45 Years",{"count":355,"type":21},16,[115],"This study aims to determine how flywheel-based inertial training (FIT) implemented according to principles of velocity-based training (VBT) and High-Intensity Interval Training (HIIT) affects disuse-induced physical de-conditioning including loss of voluntary muscle strength, aerobic capacity, and balance regulation.",[359,25],"Muscle Atrophy",[361,362,363,364],"spaceflight","unweighting","disuse","exercise","2025-10-22",{"date":367,"type":36},"2025-10-24",{"date":369,"type":36},"2024-10-23",{"date":371,"type":21},"2026-09-01",{"name":373,"class":72},"Lance Bollinger",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":352,"enrollmentInfo":380,"targetDuration":4,"studyType":113,"phases":382,"briefSummary":383,"conditions":384,"keywords":387,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":408},"100604137","effects-of-early-rehabilitation-using-blood-flow-restriction-andor-surface-electromyography-biofeedback-on-quadriceps-activation-and-strength-after-anterior-cruciate-ligament-reconstruction-a-multicenter-randomized-controlled-trial-100604137","NCT07145606","Effects of Early Rehabilitation Using Blood Flow Restriction and\u002For Surface Electromyography Biofeedback on Quadriceps Activation and Strength After Anterior Cruciate Ligament Reconstruction: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18-35 years.\n\nFirst-time anterior cruciate ligament (ACL) reconstruction.\n\nPre-injury activity level Tegner ≥ 6.\n\nMarx activity scale ≥ 12.\n\nBody mass index \\\u003C 35.\n\nWith or without associated meniscal injury.\n\nExclusion Criteria:\n\n* Revision ACL surgery.\n\nConcurrent repair of other knee ligaments.\n\nNeurological or systemic musculoskeletal disorders.\n\nContraindications to blood flow restriction (BFR) or surface EMG monitoring\u002Fbiofeedback.\n\nPregnancy or lactation.\n\nLanguage barrier or cognitive impairment preventing valid informed consent; vulnerable populations not enrolled.",{"count":381,"type":21},200,[115],"Many patients experience quadriceps inhibition after anterior cruciate ligament (ACL) reconstruction, delaying strength recovery, hindering return to sport, and potentially increasing the risk of re-injury. Two rehabilitation strategies-low-load blood flow restriction (BFR) training and surface electromyography (sEMG) biofeedback-aim to enhance neuromuscular activation and strength while limiting joint load. However, comparative and combined evidence in pragmatic, multicenter settings remains limited.\n\nAMIRACL is a multicenter, prospective, randomized, controlled, parallel-group trial with four arms enrolling 200 adults (18-35 years) undergoing a first-time ACL reconstruction. Participants are randomized with center stratification; outcome assessors are blinded to allocation. The four groups are: (1) standard rehabilitation; (2) standard + early BFR; (3) standard + early sEMG biofeedback; and (4) standard + combined BFR and sEMG biofeedback. Interventions begin about 2 weeks postoperatively, are delivered over 6 weeks at three supervised sessions per week, and are integrated into contemporary ACL rehabilitation. BFR uses individualized, auto-regulated cuff pressure during low-load isometric and then dynamic exercises. sEMG biofeedback provides real-time visual and\u002For auditory feedback to optimize quadriceps recruitment during targeted tasks. The combined arm receives both modalities concurrently.\n\nThe primary objective is to compare quadriceps activation (sEMG) and maximal isometric knee extensor strength between groups at 3 and 6 months. Secondary objectives include return-to-sport readiness and patient-reported function (e.g., ACL-RSI, IKDC), broader knee outcomes (e.g., KOOS, Lysholm), adherence and adverse events across arms, and ACL re-injury (ipsilateral graft rupture or contralateral ACL injury) within 2 years. Longer-term patient-reported quality of life is explored up to 5 years.\n\nKey eligibility criteria include age 18-35 years, first ACL reconstruction, and preinjury sport participation; major exclusions include revision ACL surgery, concomitant multi-ligament repair, neuromuscular disorders, and contraindications to BFR or sEMG. The planned sample size is 200 (50 per arm), powered to detect a clinically meaningful between-group difference in quadriceps activation. Analyses will follow the intention-to-treat principle using mixed-effects models for repeated measures. The study is conducted under Good Clinical Practice and applicable Swiss regulations; all participants provide written informed consent. Overall, AMIRACL will determine whether early BFR, sEMG biofeedback, or their combination meaningfully improves quadriceps activation, strength, and clinical recovery after ACL reconstruction compared with standard rehabilitation alone.",[385,386,25],"Anterior Cruciate Ligament Injuries","Knee Injuries",[388,389,386,390,391,392,393,394,395,396,397,398],"Anterior Cruciate Ligament","ACL Reconstruction","Rehabilitation","Quadriceps Muscle","Quadriceps Activation","Muscle Strength","Arthrogenic Muscle Inhibition","Blood Flow Restriction Training","Surface Electromyography","Biofeedback","Return to Sport","2025-08-21",{"date":401,"type":36},"2025-08-28",{"date":403,"type":21},"2026-01-02",{"date":405,"type":21},"2031-01-02",{"name":407,"class":72},"Haute Ecole ARC Sante",4,{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":353,"enrollmentInfo":415,"targetDuration":4,"studyType":113,"phases":417,"briefSummary":418,"conditions":419,"keywords":422,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":44},"100594948","effects-of-biofeedback-guided-training-on-muscle-strength-and-postural-alignment-in-upper-cross-syndrome-100594948","NCT07026084","Effects of Biofeedback-Guided Training on Muscle Strength and Postural Alignment in Upper Cross Syndrome.","Inclusion Criteria:\n\n* • Adults aged 25-45 years with both genders.\n\n  * Individuals meeting the following diagnostic criteria for upper cross syndrome will be included:\n  * Reduced strength of deep cervical flexors = unable to maintain pressure beyond 22-24 mm Hg (assessed via cranio-cervical flexion test).\n  * Limited cervical range of motion (Flexion: \\\u003C 80 degrees, Extension: \\\u003C 70 degrees, Rotation: \\\u003C 90 degrees on both sides, Lateral Flexion: \\\u003C 20 degrees)\n  * Postural deviations: forward head posture (CVA \\\u003C50 degrees), increased thoracic kyphosis (via flexi curve \\>45 degrees).\n  * Neck pain with a duration of over 3 months\n\nExclusion Criteria:\n\n* • History of recent neck surgery or injury.\n\n  * Patients with neurological disorders affecting muscle tone.\n  * Involvement in other physical therapy programs focused on UCS.\n  * Diagnosed musculoskeletal condition that could impact muscle performance.",{"count":416,"type":21},56,[115],"This randomized controlled trial investigates the effects of biofeedback-guided training versus conventional therapy on muscle strength and postural alignment in patients with Upper Cross Syndrome. The study includes adults aged 25-45 years meeting diagnostic criteria for UCS, such as weak deep cervical flexors, restricted cervical ROM, forward head posture, increased thoracic kyphosis, and chronic neck pain \\>3 months. Participants are divided into two groups: Group A biofeedback training and Group B conventional therapy, receiving 12 sessions over 4 weeks ,3sessions\u002Fweek. Assessments are conducted at baseline, post-1st session, and weekly intervals using standardized measures.The study aims to compare the efficacy of biofeedback-guided training in improving strength and posture in UCS patients.",[420,25,421],"Upper Extremity Problem","Postural Kyphosis",[423,424,425,426,427],"upper cross syndrome","forward head posture","young adults","bio feedback guided training","postural alignment","2025-08-18",{"date":430,"type":36},"2025-08-22",{"date":432,"type":36},"2025-08-11",{"date":434,"type":21},"2026-01-01",{"name":436,"class":72},"Riphah International University",{"id":438,"slug":439,"hasResults":11,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":113,"phases":446,"briefSummary":447,"conditions":448,"keywords":451,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":44},"100531849","effects-of-elastic-band-resistance-exercise-on-muscle-strength-and-depression-in-hospitalized-elderly-100531849","NCT06205147","Effects of Elastic Band Resistance Exercise on Muscle Strength and Depression in Hospitalized Elderly.","Effects of Elastic Band Resistance Exercise on Muscle Strength and Depression in Hospitalized Elderly Patients.","Inclusion Criteria:\n\n1. Age of 65 years or older.\n2. Anticipated hospital stay exceeding 7 days.\n3. Able to follow instructions.\n4. Four-limb muscle strength of at least three points, and grip strength measurements with a minimum of 26 kilograms for males and 18 kilograms for females.\n\nExclusion Criteria:\n\n1. This includes individuals with cardiovascular diseases such as acute myocardial infarction, unstable angina, poorly controlled arrhythmias, complete atrioventricular block, acute heart failure, acute myocarditis, acute pericarditis, and other cardiac conditions.\n2. Poorly controlled hypertension, with systolic blood pressure less than 90 mmHg or greater than 200 mmHg under medication.\n3. Individuals hospitalized due to acute neurological injuries or conditions, such as epilepsy, stroke, or Parkinson's disease.\n4. Diagnosed with cognitive impairment or Alzheimer's disease.\n5. Those who require long-term ventilator support and are unable to participate in the program.\n6. Individuals with impaired consciousness who cannot cooperate.\n7. A Glasgow Coma Scale score of less than 12, or inability to correctly answer questions about person, time, place, or follow instructions.",{"count":445,"type":21},62,[115],"With improved a five-day intensive, low-resistance elastic band exercise program to evaluate its effectiveness in improving total muscle mass, upper and lower extremity muscle strength, self-perceived fear of falling, and depression among hospitalized elderly individuals. This study is a random control trial. Data collection includes elderly patient's total muscle mass, upper and lower extremity muscle strength, self-perceived fear of falling, and depression among hospitalized. The total muscle mass and upper and lower extremity muscle strength will be calculated in kilograms.",[449,25,450],"Resistance Exercise","Functional Decline",[452,453,454,455,456],"resistance exercise","hospitalized elderly","muscle strength","depression","Functional decline","2025-07-21",{"date":459,"type":36},"2025-07-24",{"date":461,"type":36},"2025-03-05",{"date":463,"type":21},"2025-12-31",{"name":465,"class":72},"National Taiwan University",{"id":467,"slug":468,"hasResults":11,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":326,"enrollmentInfo":473,"targetDuration":4,"studyType":113,"phases":475,"briefSummary":477,"conditions":478,"keywords":482,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":44},"100510693","phase-4-depo-medrol-on-psoas-after-llif-100510693","NCT05929755","Depo-Medrol on Psoas After LLIF","Effect of Depo-Medrol Application on the Psoas Muscle After Transpsoas LLIF on Post-operative Hip Flexor Weakness, Thigh Pain and Numbness","Inclusion Criteria:\n\n* Patients from the practices of Drs. Singh, Mallozzi, Moss\n* Transpsoas (PTP or LTP) lateral lumbar interbody fusion (LLIF) 1-3 disc levels with posterior instrumentation (Open or MIS) with or without laminectomy, must include L3-4 and\u002For L4-5\n* Patients who agree to be a part of the study\n* Patients with lumbar disc degeneration\n* Patients between ages of 18 and 75\n\nExclusion Criteria:\n\n* Scoliosis \\>10°\n* Spondylolisthesis \\>Grade 1\n* Flatback deformity\n* Patients with insulin dependent diabetes\n* Patients with \\>3 levels of fusion\n* Alternative interbodies\n* Chronic oral steroid users\n* Patients with allergy\u002Fintolerance to depo-medrol or other steroids\n* Patients requiring bilateral transpsoas approaches\n* Patients with ipsilateral symptomatic hip pathology\n* Revision fusion procedures\n* Cases involving trauma, tumor, or infection\n* Patient's not capable of providing consent themselves\n* Non-fluent English speakers (for consenting reasons)\n* Patients who are lost to follow-up before the two year follow up period",{"count":474,"type":21},80,[476],"PHASE4","The goal of this study is to determine the effects of a corticosteroid administered to the psoas muscle following a transpsoas lateral lumbar interbody fusion (LLIF) on postoperative hip flexor weakness and thigh pain and numbness.",[25,479,480,481],"Pain, Postoperative","Paresthesia","Pain, Muscle",[483,484,485,486,487,488,489,490,491],"lateral lumbar interbody fusion","LLIF","Depo-Medrol","corticosteroid","lumbar spine","psoas muscle","postoperative hip flexor weakness","postoperative thigh pain","postoperative thigh numbness","2025-07-18",{"date":459,"type":36},{"date":495,"type":36},"2023-05-12",{"date":497,"type":21},"2027-05",{"name":499,"class":72},"Hardeep Singh",{"id":501,"slug":502,"hasResults":11,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":510,"conditions":511,"keywords":513,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":44},"100598320","early-assessment-of-quadriceps-muscle-recovery-by-dynamometry-and-3d-ultrasound-in-intensive-care-patients-under-invasive-mechanical-ventilation-100598320","NCT07069959","Early Assessment of Quadriceps Muscle Recovery by Dynamometry and 3D Ultrasound in Intensive Care Patients Under Invasive Mechanical Ventilation","Early Assessment of Quadriceps Muscle Recovery by Dynamometry and 3D Ultrasound in Intensive Care Patients Under Invasive Mechanical Ventilation: A Monocentric and Prospective Study.","DYNAMOREA","Inclusion Criteria:\n\n* Adults aged \\> 18 years\n* Hospitalized in an ICU\n* Treated with invasive mechanical ventilation (MV) for at least 4 days during their stay (may be extubated at the time of inclusion)\n* Conscious and cooperative patients: ability to respond appropriately to the following commands: open and close eyes, look at me, nod your head, stick out your tongue, raise your eyebrows when I count to five\n* MRC score ≥ 3\u002F5 for the \"Leg Extension\" function on either the left or right side\n* Informed consent obtained (no opposition)\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Fracture or amputation of a lower limb\n* Acute or chronic brain or spinal cord injury responsible for hemiplegia or paraplegia\n* Unstable spinal injury\n* Neurodegenerative or chronic neurological disease\n* Guillain-Barré Syndrome\n* Myasthenia Gravis\n* Acute deep vein thrombosis of the lower limbs treated within the last 48 hours\n* Pre-existing motor deficit in a lower limb before the ICU stay, of any cause\n* Incarcerated or legally protected individuals (guardianship, curatorship)\n* Individuals without social protection",{"count":509,"type":21},100,"Patients in intensive care often develop acquired muscle weakness (ICUAW or Intensive Care Unit Acquired Weakness) due to immobilization and muscle atrophy. Early mobilization can help reduce weakness and improve functional recovery, but practices vary. Muscle strength assessment, particularly using the MRC (Medical Research Council) score, is crucial, though it has precision limitations. Additional methods, such as manual dynamometry and functional scales, are needed to better track muscle recovery. The quadriceps, important for function, requires early evaluation, but there is a lack of specific data in intensive care to predict medium-term functional recovery.",[512,25],"Intensive Care Unit Acquired Weakness",[514,515,516,517,518,519],"dynamometry","muscle weakness","intensive care","functional recovery","invasive mechanical ventilation","3D ultrasound","2025-07-16",{"date":522,"type":36},"2025-07-17",{"date":524,"type":21},"2025-08-01",{"date":526,"type":21},"2026-11-01",{"name":528,"class":72},"Nantes University Hospital",{"id":530,"slug":531,"hasResults":11,"nctId":532,"briefTitle":533,"officialTitle":533,"acronym":534,"eligibilityCriteria":535,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":113,"phases":538,"briefSummary":539,"conditions":540,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":548,"locationsCount":44},"100575408","post-intensive-care-optimization-through-lifestyle-intervention-100575408","NCT06771895","Post Intensive Care Optimization Through Lifestyle Intervention","PICOLI","Inclusion Criteria:\n\n* Aged 18 years and older\n* Minimum ICU length of stay of 5 days and\u002For mechanically ventilated for a minimum of 2 days\n* Persistent physical complaints\n* Community-dwelling, living independently (non-assisted)\n* Mentally competent with a Mini-Mental State Examination (MMSE) score of ≥24\n* Willing to participate in a 20-week multimodal lifestyle intervention\n\nExclusion Criteria:\n\n* Any medical condition that may interfere with the safety of the subjects during exercise or any condition that interferes with assessment of the outcome parameters, in the investigators' judgement in consultation with the responsible physician or treating physician\u002Fspecialist. In case of a contra-indication for MRI (e.g., a pacemaker), subjects will be excluded from this measurement but not necessarily from the study.\n* Any medical condition or circumstance where supplementation with the nutritional supplement is potentially contra-indicated.\n* Known allergy to any of the ingredients present in the nutritional supplement.\n* Simultaneous use of other nutritional supplements during the study period (i.e., unwillingness to stop for the duration of the study).\n* Current participation in other scientific research that conflicts with this study (e.g. intervention studies or weight management studies).\n* No permission to request information from the general practitioner\u002Ftreating specialist(s) about medical history, medication use.\n\n  * Pregnancy.",{"count":537,"type":21},35,[115],"The quality of the intensive care unit (ICU) has been steadily improving over the years. Although improvements in the acute treatment of critically ill patients have been made, a large number of ICU survivors suffer from severe physical, cognitive and mental health problems persisting months to years after leaving the ICU. Physical impairments occur the most and can be very severe, greatly affecting activities in daily life and subsequently the perceived quality of life of ICU survivors. Although there is an increased awareness of long-term complaints following ICU stay, there is currently a knowledge gap on how to enhance the recovery of ICU survivors 6 to 12 months post-ICU discharge. The overall objective of the current study is to establish the extent of health and functional improvements that can be obtained with an optimized, combined exercise and nutritional intervention in ICU survivors 6 to 12 months post-ICU discharge.",[541,25],"ICU Survivor","2025-05-02",{"date":544,"type":36},"2025-05-07",{"date":546,"type":21},"2025-06-01",{"date":257,"type":21},{"name":549,"class":72},"Maastricht University Medical Center",{"id":551,"slug":552,"hasResults":11,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":556,"eligibilityCriteria":557,"healthyVolunteers":11,"sex":16,"minAge":109,"maxAge":558,"enrollmentInfo":559,"targetDuration":4,"studyType":113,"phases":561,"briefSummary":562,"conditions":563,"keywords":566,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":44},"100455153","achilles-tendon-for-the-treatment-of-gluteus-medius-insufficiency-100455153","NCT05206838","Achilles Tendon for the Treatment of Gluteus Medius Insufficiency","Achilles Tendon Homograft for the Treatment of Gluteus Medius Insufficiency After Hip Replacement","HLS","Inclusion Criteria:\n\n* Persisting limping with positive Trendelenburg's sign for at least 12 months after total hip arthroplasty\n* Rupture\u002Favulsion of the gluteus medius tendon verified with ultrasound or MRI\n* Leg length discrepancy of less than 1 cm\n* Femoral offset discrepancy of less than 25%\n\nExclusion Criteria:\n\n* Neuromuscular disorders","80 Years",{"count":560,"type":21},44,[115],"Residual limping after total hip arthroplasty is a serious complication that lacks effective treatment. The purpose of this study is to evaluate a surgical treatment for residual limping and compare its results with non-surgical treatment. Our hypothesis is that surgical treatment followed by physiotherapy increases hip function and reduces limping compared with non-surgical treatment with physiotherapy alone.",[564,25,359,565],"Arthroplasty Complications","Muscle Tear",[567,568,569,570],"Gluteus medius","Limp","Abductor","Trendelenburg","2025-04-05",{"date":573,"type":36},"2025-04-08",{"date":575,"type":36},"2022-06-29",{"date":577,"type":21},"2028-12",{"name":579,"class":72},"Sahlgrenska University Hospital",{"id":581,"slug":582,"hasResults":11,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":11,"sex":16,"minAge":109,"maxAge":558,"enrollmentInfo":588,"targetDuration":4,"studyType":113,"phases":590,"briefSummary":591,"conditions":592,"keywords":595,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":605,"locationsCount":44},"100455907","the-role-of-surgical-approach-on-residual-limping-after-total-hip-arthroplasty-100455907","NCT05216666","The Role of Surgical Approach on Residual Limping After Total Hip Arthroplasty","Abductor Insufficiency After Total Hip Arthroplasty; Risk Factors and Diagnosis","HSS","Inclusion Criteria:\n\n* Primary unilateral osteoarthritis of the hip scheduled for total hip arthroplasty.\n* Ability to understand and write swedish.\n\nExclusion Criteria:\n\n* Impaired funktion of the contralateral hip or knees causing limping.\n* Neuromuscular diseases\n* Postoperative leg length discrepancy excceding 1 cm\n* Postoperative discrepancy in femoral offset exceeding 25% of the femoral offset of the contralateral hip.",{"count":589,"type":21},580,[115],"Residual limping after total hip arthroplasty is empirically associated with the use of lateral approach but has been reported in litterature even with the use of posterior approach. The purpose of this clinical trial is to compare the risk of residual limping one year after total hip arthropasty between lateral and posterior approach.",[593,25,359,594,564],"Hip Osteoarthritis","Muscle Injury",[596,597,598,570,599],"abductor","approach","limp","gluteus medius",{"date":601,"type":36},"2025-04-09",{"date":603,"type":36},"2022-05-11",{"date":577,"type":21},{"name":579,"class":72},{"id":607,"slug":608,"hasResults":11,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":612,"eligibilityCriteria":613,"healthyVolunteers":11,"sex":16,"minAge":614,"maxAge":615,"enrollmentInfo":616,"targetDuration":4,"studyType":113,"phases":617,"briefSummary":618,"conditions":619,"keywords":623,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":634,"locationsCount":44},"100576113","effect-of-nerve-stimulation-on-sciatic-nerve-injury-pediatric-patients-100576113","NCT06781060","Effect of Nerve Stimulation on Sciatic Nerve Injury Pediatric Patients","Effect of Faradic Nerve Stimulation on Post-Injection Sciatic Nerve Injury Pediatric Patients","PISNI","Inclusion Criteria:\n\n* Pediatric patients diagnosed with Post-Injection Sciatic Nerve Injury (PISNI) caused by improper intramuscular (IM) injections.\n* Children aged 3 to 19 years.\n* Parental consent for participation in the study.\n* Assent from the child (when applicable), depending on the age and understanding of the participant.\n\nExclusion Criteria:\n\n* Children requiring surgical intervention for severe neurotmesis.\n* Patients with neurological or musculoskeletal conditions that may affect the outcomes (e.g., muscular dystrophy, multiple sclerosis).\n* Children who are unable to participate in physical therapy due to other medical conditions or severe limitations.\n* Children with severe systemic or other comorbid conditions that could interfere with study participation or outcome measures.","3 Years","19 Years",{"count":509,"type":21},[115],"Brief Summary The goal of this study is to learn if Faradic Nerve Stimulation (FNS) can help children recover from a condition called Post-Injection Sciatic Nerve Injury (PISNI). PISNI happens when the sciatic nerve, which controls muscles and sensation in the legs, gets injured from an injection that was given in the wrong place or in the wrong way. This injury can cause pain, muscle weakness, and problems moving the legs.\n\nThe main questions this study aims to answer are:\n\nCan Faradic Nerve Stimulation help children with PISNI recover better than regular physiotherapy alone? Does FNS reduce pain and improve movement in children with this injury? What will happen in the study?\n\nChildren with PISNI will be treated in one of two groups:\n\nGroup A will receive Faradic Nerve Stimulation along with regular physiotherapy.\n\nGroup B will receive only regular physiotherapy and a similar treatment called Transcutaneous Electrical Nerve Stimulation (TENS).\n\nBoth treatments will be given by healthcare professionals in a safe and comfortable environment. Participants will be asked to attend therapy sessions for a few months and will be checked regularly to see how well they are recovering.\n\nWhy is this study important?\n\nPost-Injection Sciatic Nerve Injury is common in children, especially in countries where healthcare providers may not be properly trained. This can lead to long-term problems, including pain and difficulty walking. Standard physiotherapy helps but doesn't always work well enough. By testing Faradic Nerve Stimulation, this study hopes to find a treatment that helps nerves heal faster and more completely, especially in children who need it most.\n\nThe findings from this study could lead to better treatments for nerve injuries in children, particularly in areas where healthcare resources are limited. If FNS works well, it could be a new way to help children recover and live pain-free lives.",[620,621,25,622],"Leg Pain","Peripheral Nerve Discontinuities","Sciatic Nerve Compression",[612,624,625,626,627],"FNS","ES","Peripheral Nerve Injury","Sciatic Nerve Traumatic Injury","2025-01-31",{"date":630,"type":36},"2025-02-04",{"date":632,"type":36},"2024-11-18",{"date":571,"type":21},{"name":635,"class":72},"Azeem Hospital, Multan",{"id":637,"slug":638,"hasResults":11,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":4,"eligibilityCriteria":642,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":164,"enrollmentInfo":643,"targetDuration":4,"studyType":113,"phases":645,"briefSummary":646,"conditions":647,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":650,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":656,"locationsCount":44},"100567239","foot-muscles-training-in-sclerosis-100567239","NCT06665607","Foot Muscles Training in Sclerosis","Effects of Intrinsic Foot Muscles Training in Improving Stability in Multiple Sclerosis Patients","Inclusion Criteria:\n\n* Patients with moderate neurological disability as scored by the Expanded Disability Status Scale (EDSS), ranging from 3.0 to 6.0\n\nExclusion Criteria:\n\n* Cognitive disturbances that could affect the performance of any of the tests or questionnaires included in the study\n* Diagnosis of visual or vestibular disorders that could affect patient stability\n* Change in Multiple Sclerosis-specific medication in the 2 months prior to the start of the study\n* Acute relapse in the 2 months prior to the start of the study\n* Traumatologic or orthopaedic disorders that could negatively affect balance.",{"count":644,"type":21},34,[115],"The study tries to assess the efficacy of an 8-week IFM training programme on stability in patients diagnosed with Multiple Sclerosis",[648,25,649],"Multiple Sclerosis","Training Group, Sensitivity",{"date":651,"type":36},"2024-11-01",{"date":653,"type":21},"2024-11-04",{"date":655,"type":21},"2025-07-15",{"name":657,"class":72},"Inés Llamas-Ramos",{"id":659,"slug":660,"hasResults":11,"nctId":661,"briefTitle":662,"officialTitle":663,"acronym":4,"eligibilityCriteria":664,"healthyVolunteers":80,"sex":53,"minAge":665,"maxAge":4,"enrollmentInfo":666,"targetDuration":4,"studyType":113,"phases":667,"briefSummary":668,"conditions":669,"keywords":671,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":682,"locationsCount":44},"100565614","whole-body-vibration-in-middle-aged-men-100565614","NCT06644469","Whole Body Vibration in Middle Aged Men","Effects of Whole-Body Vibration on Bone Mineral Density, Hand Grip Strength, and Vitamin D Levels in Middle-Aged Men: a Preliminary Clinical Trial","Inclusion Criteria:\n\n* Male participants aged 50 years or older\n* Participants with physical activity or exercise program involvement\n* Participants with no history of serious medical conditions such as tumors, fractures, epilepsy, cardiac disease, or stroke within the past year.\n* Participants must be non-smokers and not receiving hormone or calcium supplement therapy\n\nExclusion Criteria:\n\n* Participants unable to stand on the WBV platform\n* Participants with conditions contraindicating vibration therapy\n* Participants participating in other clinical trials","50 Years",{"count":644,"type":21},[115],"This study aims of this clinical trial is to evaluate the effect of an 8-week Whole Body Vibration (WBV) intervention on Bone Mineral Density (BMD), hand grip strength, and vitamin D levels in middle-aged men. Findings from this study will contribute to understanding whether WBV is a viable alternative to conventional exercise, especially for those with limitations in physical activity.\n\nStudy Objectives:\n\n• Primary Objective: To assess the effectiveness of an 8-week WBV intervention in improving BMD, hand grip strength, and vitamin D levels compared to a placebo intervention.",[670,25],"Bone Density",[672,670,673,674,393],"Pilot Study","Vibration Therapy","Vitamin D","2024-10-16",{"date":677,"type":36},"2024-10-18",{"date":679,"type":21},"2024-10-15",{"date":681,"type":21},"2024-12-15",{"name":683,"class":72},"Jouf University",{"id":685,"slug":686,"hasResults":11,"nctId":687,"briefTitle":688,"officialTitle":688,"acronym":4,"eligibilityCriteria":689,"healthyVolunteers":80,"sex":16,"minAge":54,"maxAge":18,"enrollmentInfo":690,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":691,"conditions":692,"keywords":694,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":700,"lastUpdatePostDateStruct":701,"startDateStruct":702,"completionDateStruct":703,"leadSponsor":705,"locationsCount":4},"100563877","effect-of-the-presence-of-dynapenia-on-posture-spine-muscle-elasticity-strength-and-endurance-in-young-adults-100563877","NCT06621875","Effect Of The Presence Of Dynapenia On Posture, Spine Muscle Elasticity, Strength And Endurance In Young Adults","Inclusion Criteria:\n\n* Being between the ages of 18-25\n* Filling out all the survey questions\n\nExclusion Criteria:\n\n* Presence of chronic diseases that may affect the musculoskeletal system (diabetes, heart disease, neurological disorders)\n* Use of medications that may affect muscle functions (corticosteroids, muscle relaxants)\n* Presence of serious musculoskeletal injury within the last six months\n* Presence of surgery and\u002For pain related to the musculoskeletal system\n* History of eating disorders such as anorexia nervosa, bulimia nervosa were defined as exclusion criteria",{"count":294,"type":21},"The aim of the present study was to determine the effect of dynapenia on posture, spinal muscle elasticity, strength and endurance in young adults.",[693,25,86],"Dynapenia",[695,86,696,697,698,693,699],"Muscle strength","Posture","Muscle elasticity","Muscle endurance","Hand Grip","2024-10-13",{"date":675,"type":36},{"date":651,"type":21},{"date":704,"type":21},"2025-10-01",{"name":706,"class":72},"Aynur Ayazzade",{"id":708,"slug":709,"hasResults":11,"nctId":710,"briefTitle":711,"officialTitle":711,"acronym":712,"eligibilityCriteria":713,"healthyVolunteers":80,"sex":16,"minAge":110,"maxAge":4,"enrollmentInfo":714,"targetDuration":4,"studyType":113,"phases":716,"briefSummary":717,"conditions":718,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":720,"lastUpdatePostDateStruct":721,"startDateStruct":723,"completionDateStruct":725,"leadSponsor":727,"locationsCount":44},"100459513","sarcopedia---sarcopenia-diagnostics-in-aging-medicine-100459513","NCT05263596","SARCOPEDIA - Sarcopenia Diagnostics in Aging Medicine","SARCOPEDIA","Inclusion Criteria:\n\nThe investigators aim to include patients ≥ 65 years old newly admitted for study eligibility at the UAFP.\n\nExclusion Criteria:\n\n* Lack of informed written consent\n* Implanted defibrillation device\n* Implanted pacemaker\n* Acute sepsis or severe volume overload\n* Life expectancy of \\\u003C 3 months according to treating doctor\n* bedridden\n* Plasters or bandages that cannot be removed from the feet or hands\n* Isolated patients (contact and aerosol)\n* Measurement is not possible due to organizational reasons\n* Inability to follow the procedures, e.g. due to language problems, psychological disorders",{"count":715,"type":21},120,[115],"Musculoskeletal aging is one of the major responsibilities and challenges for public health. In particular, sarcopenia correlates with an increased risk of falls and increased morbidity and mortality. With regard to screening for sarcopenia, the guidelines of the European Working Group on Sarcopenia in Older People (EWGSOP2) refer to algorithmic case finding, diagnosis, and quantification of the severity of sarcopenia in clinical. While functional measurements are more difficult to standardize and associated with higher variability, Dual-energy X-ray absorptiometry (DXA) is considered a highly accurate method, even referred to as the \"gold standard\" to determine muscle mass in the scientific literature. Nevertheless, DXA, which is routinely used, shows inconsistent correlation with functional decline in muscle strength. Another method of muscle quantification is bioelectrical impedance analysis (BIA), a simple, portable instrument that is more readily available and applicable due to its lower cost. However, it tends to overestimate muscle mass and is also more susceptible to a person's hydration status. Because of these difficulties, recent research has focused on the potential of using shear wave elastography. This method indirectly serves to quantify the rapid type II muscle fibers in order to make statements about the muscle quality because an age-related decrease in type II muscle fibers is associated with a more frequent fall frequency.\n\nFirst, the investigators will define three different categories according to the EWGSOP 2 guidelines based on the muscle strength (grip strength, assessed by pneumatic hand dynamometer) and muscle mass (Appendicular skeletal muscle mass, assessed by BIA): \"No Sarcopenia\", \"Probable Sarcopenia\" and \"Confirmed Sarcopenia\". Within these categories, the Investigators would like to establish a multivariate data analysis of different functional measurements with quantitative imaging results. This exploratory trial design is intended to improve understanding within the three categories and to test proxy measurements of different patients who are ruled out for common routine measurements due to, for example, cognitive impairment or pre-existing rheumatic disease. This is essential to consider the heterogeneity of the aging society proportionally.",[86,25,719],"Frailty","2024-07-17",{"date":722,"type":36},"2024-07-18",{"date":724,"type":36},"2022-07-11",{"date":726,"type":21},"2024-10-30",{"name":728,"class":72},"University Department of Geriatric Medicine FELIX PLATTER"]